We deliver market intelligence combining stock research, financial news, and earnings summaries to support data-driven investment decisions.
Supernus Pharmaceuticals Inc. (SUPN) is a mid-cap specialty pharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. As of current trading on 2026-04-18, SUPN shares are priced at $51.39, representing a 4.41% gain from the previous closing level. This analysis outlines key market context, technical support and resistance levels, and potential near-term scenarios for the stock, with no recent earnings data available as of the publication da
Supernus Pharmaceuticals (SUPN) Stock DCF Valuation (Creeps Higher) 2026-04-18 - Jurik MA
SUPN - Stock Analysis
4901 Comments
1077 Likes
1
Jahlil
Engaged Reader
2 hours ago
{协议答案}
👍 279
Reply
2
Normalea
Consistent User
5 hours ago
{协议答案}
👍 270
Reply
3
Quinterius
Expert Member
1 day ago
{协议答案}
👍 178
Reply
4
Jolia
Engaged Reader
1 day ago
{协议答案}
👍 128
Reply
5
Malora
Expert Member
2 days ago
{协议答案}
👍 127
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.